All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
The FDA grants eFT508 Orphan Drug Designation for DLBCL
Last week, on 10th March 2017, eFT508 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of DLBCL.
eFFECTOR Therapeutics’ eFT508 is a novel, highly selective, oral, small molecule inhibitor of MAP Kinase-Interacting Kinase 1 and 2 (MNK1/2). eFT508 activates anti-tumor immunity and also blocks several oncogenic growth and proliferation pathways.
The inhibitor is currently being assessed in patients with previously treated hematological malignancies in a phase I/II dose-escalation and cohort-expansion study (NCT02937675). Primary outcome measures are to determine the Maximum Tolerated Dose (MTD) and Overall Response Rate (ORR). The estimated primary completion date is October 2018.
A similar phase I/II trial (NCT02605083) of eFT508 is also being conducted in advanced solid tumor malignancies which have progressed after prior therapy and have no potential for cure with other therapy.
References
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?